Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study

for the DARWIN-T2D network

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In randomized controlled trials (RCTs), sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to confer glycaemic and extra-glycaemic benefits. The DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes) study was a multicentre retrospective study designed to evaluate the baseline characteristics of patients receiving dapagliflozin vs those receiving selected comparators (dipeptidyl peptidase-4 inhibitors, gliclazide, or glucagon-like peptide-1 receptor agonists), and drug effectiveness in routine clinical practice. From a population of 281 217, the analysis included 17 285 patients initiating dapagliflozin or comparator glucose-lowering medications (GLMs), 6751 of whom had a follow-up examination. At baseline, participants starting dapagliflozin were younger, had a longer disease duration, higher glycated haemoglobin (HbA1c) concentration, and a more complex history of previous GLM use, but the clinical profile of patients receiving dapagliflozin changed during the study period. Dapagliflozin reduced HbA1c by 0.7%, body weight by 2.7 kg, and systolic blood pressure by 3.0 mm Hg. Effects of comparator GLMs were also within the expected range, based on RCTs. This real-world study shows an initial channelling of dapagliflozin to difficult-to-treat patients. Nonetheless, dapagliflozin provided significant benefits with regard to glucose control, body weight and blood pressure that were in line with findings from RCTs.

Original languageEnglish
Pages (from-to)1781-1786
Number of pages6
JournalDiabetes, Obesity and Metabolism
Volume20
Issue number7
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Multicenter Studies
Retrospective Studies
Glucose
Randomized Controlled Trials
Blood Pressure
Sodium-Glucose Transporter 2
Body Weight
Gliclazide
Dipeptidyl-Peptidase IV Inhibitors
Symporters
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Glycosylated Hemoglobin A
Type 2 Diabetes Mellitus
Pharmaceutical Preparations
Population

Keywords

  • cohort study
  • dapagliflozin
  • glycaemic control
  • observational study
  • type 2 diabetes
  • weight control

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Use and effectiveness of dapagliflozin in routine clinical practice : An Italian multicentre retrospective study. / for the DARWIN-T2D network.

In: Diabetes, Obesity and Metabolism, Vol. 20, No. 7, 01.07.2018, p. 1781-1786.

Research output: Contribution to journalArticle

@article{f36dd1c9f54f4bdeb9776840bce258e8,
title = "Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study",
abstract = "In randomized controlled trials (RCTs), sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to confer glycaemic and extra-glycaemic benefits. The DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes) study was a multicentre retrospective study designed to evaluate the baseline characteristics of patients receiving dapagliflozin vs those receiving selected comparators (dipeptidyl peptidase-4 inhibitors, gliclazide, or glucagon-like peptide-1 receptor agonists), and drug effectiveness in routine clinical practice. From a population of 281 217, the analysis included 17 285 patients initiating dapagliflozin or comparator glucose-lowering medications (GLMs), 6751 of whom had a follow-up examination. At baseline, participants starting dapagliflozin were younger, had a longer disease duration, higher glycated haemoglobin (HbA1c) concentration, and a more complex history of previous GLM use, but the clinical profile of patients receiving dapagliflozin changed during the study period. Dapagliflozin reduced HbA1c by 0.7{\%}, body weight by 2.7 kg, and systolic blood pressure by 3.0 mm Hg. Effects of comparator GLMs were also within the expected range, based on RCTs. This real-world study shows an initial channelling of dapagliflozin to difficult-to-treat patients. Nonetheless, dapagliflozin provided significant benefits with regard to glucose control, body weight and blood pressure that were in line with findings from RCTs.",
keywords = "cohort study, dapagliflozin, glycaemic control, observational study, type 2 diabetes, weight control",
author = "{for the DARWIN-T2D network} and Fadini, {Gian Paolo} and Giancarlo Zatti and Ileana Baldi and Daniele Bottigliengo and Agostino Consoli and Andrea Giaccari and Giorgio Sesti and Angelo Avogaro",
year = "2018",
month = "7",
day = "1",
doi = "10.1111/dom.13280",
language = "English",
volume = "20",
pages = "1781--1786",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Use and effectiveness of dapagliflozin in routine clinical practice

T2 - An Italian multicentre retrospective study

AU - for the DARWIN-T2D network

AU - Fadini, Gian Paolo

AU - Zatti, Giancarlo

AU - Baldi, Ileana

AU - Bottigliengo, Daniele

AU - Consoli, Agostino

AU - Giaccari, Andrea

AU - Sesti, Giorgio

AU - Avogaro, Angelo

PY - 2018/7/1

Y1 - 2018/7/1

N2 - In randomized controlled trials (RCTs), sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to confer glycaemic and extra-glycaemic benefits. The DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes) study was a multicentre retrospective study designed to evaluate the baseline characteristics of patients receiving dapagliflozin vs those receiving selected comparators (dipeptidyl peptidase-4 inhibitors, gliclazide, or glucagon-like peptide-1 receptor agonists), and drug effectiveness in routine clinical practice. From a population of 281 217, the analysis included 17 285 patients initiating dapagliflozin or comparator glucose-lowering medications (GLMs), 6751 of whom had a follow-up examination. At baseline, participants starting dapagliflozin were younger, had a longer disease duration, higher glycated haemoglobin (HbA1c) concentration, and a more complex history of previous GLM use, but the clinical profile of patients receiving dapagliflozin changed during the study period. Dapagliflozin reduced HbA1c by 0.7%, body weight by 2.7 kg, and systolic blood pressure by 3.0 mm Hg. Effects of comparator GLMs were also within the expected range, based on RCTs. This real-world study shows an initial channelling of dapagliflozin to difficult-to-treat patients. Nonetheless, dapagliflozin provided significant benefits with regard to glucose control, body weight and blood pressure that were in line with findings from RCTs.

AB - In randomized controlled trials (RCTs), sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to confer glycaemic and extra-glycaemic benefits. The DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes) study was a multicentre retrospective study designed to evaluate the baseline characteristics of patients receiving dapagliflozin vs those receiving selected comparators (dipeptidyl peptidase-4 inhibitors, gliclazide, or glucagon-like peptide-1 receptor agonists), and drug effectiveness in routine clinical practice. From a population of 281 217, the analysis included 17 285 patients initiating dapagliflozin or comparator glucose-lowering medications (GLMs), 6751 of whom had a follow-up examination. At baseline, participants starting dapagliflozin were younger, had a longer disease duration, higher glycated haemoglobin (HbA1c) concentration, and a more complex history of previous GLM use, but the clinical profile of patients receiving dapagliflozin changed during the study period. Dapagliflozin reduced HbA1c by 0.7%, body weight by 2.7 kg, and systolic blood pressure by 3.0 mm Hg. Effects of comparator GLMs were also within the expected range, based on RCTs. This real-world study shows an initial channelling of dapagliflozin to difficult-to-treat patients. Nonetheless, dapagliflozin provided significant benefits with regard to glucose control, body weight and blood pressure that were in line with findings from RCTs.

KW - cohort study

KW - dapagliflozin

KW - glycaemic control

KW - observational study

KW - type 2 diabetes

KW - weight control

UR - http://www.scopus.com/inward/record.url?scp=85044511723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044511723&partnerID=8YFLogxK

U2 - 10.1111/dom.13280

DO - 10.1111/dom.13280

M3 - Article

C2 - 29516612

AN - SCOPUS:85044511723

VL - 20

SP - 1781

EP - 1786

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 7

ER -